Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review
-
- Sakakibara Ayako
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,
-
- Kohno Kei
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,
-
- Ishikawa Eri
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,
-
- Suzuki Yuka
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,
-
- Tsuyuki Yuta
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,
-
- Shimada Satoko
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,
-
- Shimada Kazuyuki
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan,
-
- Satou Akira
- Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,
-
- Takahara Taishi
- Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,
-
- Ohashi Akiko
- Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,
-
- Takahashi Emiko
- Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan,
-
- Kato Seiichi
- Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital,
-
- Nakamura Shigeo
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan,
-
- Asano Naoko
- Department of Clinical Laboratory, Nagano Prefectural Suzaka Hospital, Nagano, Japan
この論文をさがす
抄録
<p>The programmed cell death 1 (PD1)/PD1 ligand (PD-L1) axis plays an important role in tumor cell escape from immune control and has been most extensively investigated for therapeutic purposes. However, PD-L1 immunohistochemistry is still not used widely for diagnosis. We review the diagnostic utility of PD-L1 (by clone SP142) immunohistochemistry in large-cell lymphomas, mainly consisting of classic Hodgkin lymphoma (CHL) and diffuse large B-cell lymphoma (DLBCL). Neoplastic PD-L1 (nPD-L1) expression on Hodgkin and Reed-Sternberg cells is well-established among prototypic CHL. Of note, EBV+ CHL often poses a challenge for differential diagnosis from peripheral T-cell lymphoma with EBV+ non-malignant large B-cells; their distinction is based on the lack of PD-L1 expression on large B-cells in the latter. The nPD-L1 expression further provides a good diagnostic consensus for CHL with primary extranodal disease conceivably characterized by a combined pathogenesis of immune escape of tumor cells and immunodeficiency. Compared with CHL, the nPD-L1 expression rate is much lower in DLBCL, highlighting some specific subgroups of intravascular large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and EBV+ DLBCL. They consist of nPD-L1-positive and -negative subgroups, but their clinicopathological significance remains to be elucidated. Microenvironmental PD-L1 positivity on immune cells may be associated with a favorable prognosis in extranodal DLBCL. PD-L1 (by SP142) immunohistochemistry has helped us to understand the immune biology of lymphoid neoplasms possibly related by immune escape and/or immunodeficiency. However, knowledge of these issues remains limited and should be clarified for diagnostic consensus in the future.</p>
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ ａｎｄ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ
-
Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ ａｎｄ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ 61 (4), 182-191, 2021
日本リンパ網内系学会
